4WHIM trial meets primary endpoint and first key secondary endpoint, with mavorixafor achieving statistically significant and clinically relevant longer times above threshold levels for both absolute neutrophil (P
X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM Syndrome
Watch X4 Pharmaceuticals' latest callX4 Pharmaceuticals (NASDAQ:XFOR) Q1 2025 Earnings Call · Replay · Apr 30, 2025Read the transcript of X4 Pharmaceuticals (NASDAQ:XFOR) Q1 2025 Earnings CallX4 Pharmaceuticals, Inc. on 6ix
In the deck
Story so far
- X4 Pharmaceuticals Completes Enrollment in Phase 3 Mavorixafor Trial in Patients with WHIM Syndrome
- X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia at EHA 2021
- X4 Pharmaceuticals Announces Positive Preliminary Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia as Published in EHA Abstract
Earlier from X4 Pharmaceuticals
- X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
- X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer
- X4 Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host a Conference Call and Webcast to Discuss Important Upcoming Milestones on November 3, 2022
- X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor’s Broad Potential in Chronic Neutropenia (CN)
- X4 Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Later from X4 Pharmaceuticals
- X4 Pharmaceuticals Announces Proposed Public Offering
- X4 Pharmaceuticals Prices $65.0 Million Public Offering
- X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2022 Financial Results and Host a Conference Call and Webcast on March 21, 2023
- X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
- X4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM Phase 3 Clinical Data Accepted for Oral Presentation at the 2023 Annual Meeting of the Clinical Immunology Society (CIS)
Follow X4 Pharmaceuticals into a list and get an email when it puts out news.
Follow X4 Pharmaceuticals